- Home
- EPAM vs BBIO Comparison
EPAM vs BBIO Comparison
Compare EPAM & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPAM
- BBIO
- Stock Information
- Founded
- EPAM 1993
- BBIO 2015
- Country
- EPAM United States
- BBIO United States
- Employees
- EPAM N/A
- BBIO N/A
- Industry
- EPAM EDP Services
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- EPAM Technology
- BBIO Health Care
- Exchange
- EPAM Nasdaq
- BBIO Nasdaq
- Market Cap
- EPAM 8.9B
- BBIO 10.4B
- IPO Year
- EPAM 2012
- BBIO 2019
- Fundamental
- Price
- EPAM $181.01
- BBIO $65.97
- Analyst Decision
- EPAM Buy
- BBIO Strong Buy
- Analyst Count
- EPAM 14
- BBIO 19
- Target Price
- EPAM $217.50
- BBIO $74.79
- AVG Volume (30 Days)
- EPAM 914.8K
- BBIO 2.7M
- Earning Date
- EPAM 11-06-2025
- BBIO 10-29-2025
- Dividend Yield
- EPAM N/A
- BBIO N/A
- EPS Growth
- EPAM N/A
- BBIO N/A
- EPS
- EPAM 6.55
- BBIO N/A
- Revenue
- EPAM $5,297,859,000.00
- BBIO $353,780,000.00
- Revenue This Year
- EPAM $16.65
- BBIO $123.32
- Revenue Next Year
- EPAM $7.20
- BBIO $73.46
- P/E Ratio
- EPAM $27.47
- BBIO N/A
- Revenue Growth
- EPAM 14.26
- BBIO 62.46
- 52 Week Low
- EPAM $138.15
- BBIO $21.72
- 52 Week High
- EPAM $269.00
- BBIO $69.48
- Technical
- Relative Strength Index (RSI)
- EPAM 70.66
- BBIO 67.23
- Support Level
- EPAM $155.00
- BBIO $60.55
- Resistance Level
- EPAM $183.83
- BBIO $64.44
- Average True Range (ATR)
- EPAM 5.99
- BBIO 3.32
- MACD
- EPAM 2.63
- BBIO 0.23
- Stochastic Oscillator
- EPAM 89.58
- BBIO 77.24
About EPAM EPAM Systems Inc.
EPAM Systems is a global IT services firm with a focus on platform engineering, software development, and consulting services. The company used to host large engineer bases in Ukraine, Belarus, and Russia, but it now delivers from various locations across different continents. EPAM's largest market is North America, which represents approximately 60% of revenue.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.